Results 151 to 160 of about 5,803 (182)

Street-Based Hepatitis C Treatment and Patient Experiences Among Adults Experiencing Unsheltered Homelessness.

JAMA Netw Open
Natsoulis A, Nussbaum C, Howard L, Achilles D, Yurick K, Zaks C, Coulourides Kogan A.   +6 more
europepmc   +1 more source

Micro-elimination of Hepatitis C virus (HCV) infection in the General Population Cohort in rural Uganda: long-term follow-up to assess feasibility and outcomes of a screening and treatment intervention

Mugisha J, Kimono B, Lumley S, O’Hara G, Waddilove E, Wekesa C, Mgomella G, Makanga R, Ndungutse R, Nyirenda M, Davis C, Thomson E, Ocama P, Seeley J, Matthews PC, Newton R.   +15 more
europepmc   +1 more source

Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir Regimen [PDF]

Antimicrobial Agents and Chemotherapy, 2017
Interactions between simeprevir (hepatitis C virus [HCV] NS3/4A protease inhibitor) and ledipasvir (HCV NS5A replication complex inhibitor) were investigated in treatment-naive HCV genotype 1-infected patients without cirrhosis, treated with simeprevir ...
Veerle van Eygen, Sivi Ouwerkerk-Mahadevan, Frederik Nevens   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Ledipasvir/sofosbuvir

Reactions Weekly, 2018
  +13 more sources

Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir

Journal of Hepatology, 2017
BACKGROUND & AIMS: Ledipasvir/sofosbuvir combination treatment in phase III clinical trials resulted in sustained viral suppression in 94-99% of patients.
Eric Lawitz, Kris Kowdley, David Wyles   +2 more
exaly   +2 more sources

Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response [PDF]

Gastroenterology, 2016
The combination of ledipasvir and sofosbuvir has been approved for treatment of genotype 1 hepatitis C virus (HCV) infection, including an 8-week regimen for treatment-naïve patients without cirrhosis and a baseline level of HCV RNA <6 million IU/mL ...
David Nelson, Mark Sulkowski
exaly   +2 more sources

Ledipasvir/sofosbuvir

Reactions Weekly, 2017
  +8 more sources

Ledipasvir/sofosbuvir

Reactions Weekly, 2020
  +8 more sources